NINDS CDE Notice of Copyright Montreal Cognitive Assessment (MoCA)

Availability:	Universities/ Foundations/ Health Professionals/ Hospitals/Clinics/ Public Health Institutes: MoCA may be used, reproduced, and distributed, WITH prior written permission. The test should be made available free of charge.
	Commercial Entity/ Pharma sponsored research: MoCA may be used, reproduced, and distributed, WITH prior written permission and Licensing Agreement. The test should be made available free of charge.
	For additional information, please visit website: http://www.mocatest.org/ .
Classification:	Core for Stroke and Epilepsy
	Supplemental for PD
	Exploratory for HD
Short Description of Instrument:	Purpose The MoCA screens patients who present with mild cognitive complaints and normal mini-mental state examination (MMSE) scores for mild cognitive impairment (MCI). While the MMSE is a ubiquitous cognitive screening instrument, its relative insensitivity to executive dysfunction and the focal cognitive deficits that can often been seen in stroke render it suboptimal for cerebrovascular populations. In fact, a recent study demonstrated the underestimation of cognitive deficits by the MMSE versus the MoCA in individuals with TIAs and stroke in a large population based study.
	Overview The MoCA is a screening test of cognition with favorable psychometric properties. It screens eight domains: Visuospatial/executive, Naming, Memory, Attention, Language, Abstraction, Delayed recall, and Orientation.
	Time The assessment takes approximately 10 minutes.
	Scoring The total possible score is 30 points (total for each domain: Visuospatial/executive – 5, Naming – 3, Memory – None, Attention – 6, Language – 3, Abstraction – 2, Delayed recall – 5, Orientation – 6). A normal score is greater than or equal to 26 points. The suggested cut-off score [MCI or Alzheimer's disease (AD)] is any score less than 26. One point is added for an individual who has 12 years or fewer of formal education; however the total possible score remains the same. Note that additional studies of optimizing cut-points in different populations are currently underway.
	Psychometric Properties There are strong validation studies emerging across patient populations (e.g., cerebrovascular, MCI/AD, Parkinson's disease).
	Other Important Notes Available in various languages (currently 31 total).
	Raters using this at admission or discharge should develop a standard methodology and scoring instructions for use in hospital setting.

NINDS CDE Notice of Copyright Montreal Cognitive Assessment (MoCA)

References:

Nasreddine et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53:695-699

Stroke:

Luis C., Keegan A, & Mullan, M (2009). Cross validation of the Montreal cognitive assessment in community dwelling older adults residing in the southeastern US. International Journal of Geriatric Psychiatry, 24: 197-201.

Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc, 53(4): 695-699.

Naugle, R., & Kawczak, K. (1989). Limitations of the Mini-Mental State Examination. Cleveland Clinic Journal of Medicine, 56, 277-281.

Pendlebury ST, Cuthbertson FC, Welch SJ, Mehta Z, Rothwell PM. (2010). Underestimation of cognitive impairment by mini-mental state examination versus the montreal cognitive assessment in patients with transient ischemic attack and stroke: a population-based study. Stroke. 2010 Jun; 41(6):1290-3. Epub 2010 Apr 8.

Popovic, IM, Seric, V, & Demarin, V. (2007). MCI in symptomatic and asymptomatic cerebrovascular disease. J Neurol Sci, 257, 185-193.

Zadikoff, C., Fox, SH, Tang-Wai, DF, Thomsen, T., de Bie, RM, Wadia, P, Miyasaki, J., Duff-Canning, S., Lang, AE, & Marras, C. (2008). A comparison of the MMSE to the MoCA in identifying cognitive deficits in PD. Mov Disord, 23, 297-299.

HD:

Mickes L, Jacobson M, Peavy G, Eixted JT, Lessig S, Goldstein JL, Corey-Bloom J. A comparison of two brief screening measures of cognitive impairment in Huntington's disease. Movement Disorders 2010; 25:2229-22233.

Videnovic A, Bernard B, Fan W, Jaglin J, Leurgans S, Shannon KM. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease. Movement Disorders 2010; 25:401-404.